MLH1启动子高甲基化与生存结局的关联:子宫内膜癌分子靶向治疗联盟真实世界队列研究
本研究利用ECMT2数据库纳入133例晚期或复发dMMR子宫内膜腺癌患者,比较胚系/体细胞Lynch综合征突变与MLH1启动子高甲基化两组接受帕博利珠单抗或多塔利单抗治疗的应答与生存。两组客观缓解率分别为55.9%和57.6%(p=0.90),2年无进展生存率分别为68.0%和59.0%(p=0.77),2年总生存率分别为70.9%和62.2%(p=0.55)。结论提示dMMR不同机制与免疫检查点抑制剂应答及生存结局无关。
要点
- dMMR子宫内膜癌中MLH1启动子高甲基化占74.4%,Lynch综合征突变占25.6%。
- 两组客观缓解率、2年PFS和2年OS均无显著差异。
- dMMR机制不影响免疫检查点抑制剂疗效,治疗决策无需区分。
核心结论
- dMMR不同发生机制(遗传性/体细胞Lynch综合征突变 vs MLH1启动子高甲基化)与免疫检查点抑制剂应答及生存结局无显著关联。
研究设计与样本
- 研究为基于ECMT2数据库的真实世界队列研究,纳入2016至2023年接受帕博利珠单抗或多塔利单抗治疗的dMMR晚期或复发子宫内膜腺癌患者133例。
主要发现
- 全队列客观缓解率为57.1%,gLS/sLS组为55.9%,hMLH1组为57.6%(p=0.90)。
- 2年无进展生存率gLS/sLS组为68.0%,hMLH1组为59.0%(p=0.77)。
- 2年总生存率gLS/sLS组为70.9%,hMLH1组为62.2%(p=0.55)。
- 两组人口学特征、诊断分期及组织学类型相似。
关键数值与推荐
- dMMR分型:gLS/sLS共34例(25.6%),hMLH1共99例(74.4%)。
临床怎么用
- 对于晚期或复发dMMR子宫内膜腺癌,无论dMMR机制为Lynch综合征突变还是MLH1启动子高甲基化,均可考虑使用免疫检查点抑制剂治疗。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed the underlying etiology of MMR deficiency (dMMR), genetic (germline/somatic) versus epigenetic hMLH1, and associations between response rate, and survival outcomes in patients with advanced and recurrent dMMR endometrial adenocarcinoma treated with immune checkpoint inhibitors. METHODS: The Endometrial Cancer Molecularly Targeted Therapy Consortium (ECMT2) database was used to identify patients with mismatch repair deficient (dMMR) tumors treated with pembrolizumab or dostarlimab from 2016 to 2023. Cases were categorized into two groups- germline Lynch Syndrome mutation (gLS) and somatic Lynch Syndrome mutation (sLS), or MLH1 promoter hypermethylation (hMLH1). Clinical and pathologic data included patient demographics, tumor characteristics, recurrence date, survival, and treatment. RESULTS: A total of 133 patients were included: gLS/sLS (n = 34, 25.6%) or hMLH1 (n = 99, 74.4%). Demographic and tumor characteristics, including stage at diagnosis and histology were similar between groups. The response rate was 57.1% for the entire cohort [55.9% gLS/sLS, 57.6% hMLH1; (p = 0.90)]. The survival outcomes were not significantly different in the gLS/sLS and hMLH1 groups [2-year progression-free survival: 68.0% and 59.0% (p = 0.77); 2-year overall survival: 70.9% and 62.2% (p = 0.55)], respectively. CONCLUSION: Our findings suggest that response to immune checkpoint inhibitors and survival outcomes are not associated with different mechanisms of dMMR.
引用
- Borden LE, Cosgrove CM, Washington CR, et al. MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2026. PMID: 42468445. doi:10.1016/j.ygyno.2026.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。